About Pronota
Pronota is a Healthcare company based in Ghent (Belgium) founded in 2004, and was acquired by Biocartis in September 2014. Diagnostics for heart failure, pre-eclampsia, and sepsis are provided. Pronota has raised $34.75 million across 10 funding rounds from investors including Biocartis, Gimv and VIB. The company has 2 employees. The company was acqui-hired. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, In-Vitro Diagnostics and Congestive Heart Failure. Its legal entity is MyCartis NV.
Company details
Pronota NV was founded in 2004 in Ghent, Belgium, within the medical diagnostics sector. Early detection of conditions including heart failure, pre-eclampsia, and sepsis is facilitated through proprietary, non-invasive tests. Biological samples proteomes are analyzed to develop a range of diagnostic products. Operations emphasize diagnosis and personalized healthcare, with services targeted at patient validation and portfolio expansion in Europe.
- Headquarters Ghent, Belgium
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Website pronota.com
- Social LinkedIn X
- Acquired by Biocartis (Sep 2014)
- Legal Name Mycartis Nv
Funding Insights of Pronota
Pronota has successfully raised a total of $34.75M across 10 strategic funding rounds. The most recent funding activity was a Series C round of $1.8 million completed in December 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $34.75M
- Total Rounds 10
- Last Round Series C β $1.8M
- First Round $7.8M
(Apr 2006)
- Investors Count 9
All 10 funding rounds of Pronota with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2012 | $1.8M | Series C | β | β | β |
| Jan 2012 | $4.7M | Series C | β | Life Sciences Partners, Gimv | β |
| May 2010 | $1.85M | Series B | β | MSC | β |
| Jan 2010 | $2.03M | Grant | β | β | |
| Oct 2009 | $1.95M | Series B | β | β | |
| Jun 2009 | $6.04M | Series B | β | VIB | |
| Jul 2007 | $2.8M | Grant | β | β | β |
| Oct 2006 | $2.2M | Grant | β | β | β |
| Aug 2006 | $10.6M | Series A | β | β | |
| Apr 2006 | $7.8M | Series A | β | β |
10 investors in total: 10 institutional.
Investors in Pronota
Pronota has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Biocartis, Gimv and VIB.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
PE firm focusing on seed and early stage companies based out of Belgium | kbcpe.be | Brussels, Belgium | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
A venture capital firm focused on life science innovations. | mp-healthcare.com | Cambridge, United States | ||
Venture capital is provided to medical life sciences companies. | medsciencescapital.com | The Hague, Netherlands | ||
| baekelandfonds.be | ||||
VIB is recognized as a leading biotechnology research institute. | 1995 | vib.be | Ghent, Belgium | |
| infect-era.eu | ||||
Molecular assays for disease detection are developed using proprietary technology. | 2007 | biocartis.com | Mechelen, Belgium |
Investor details for Pronota
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pronota
1 people are tracked at Pronota (1 in leadership); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
Katleen Verleysen | CEO | Leadership |
Complete people profiles for Pronota
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pronota
4 dated milestones of Pronota across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Pronota is founded.
- Funding First funding round of $7.8M.
- Funding Latest funding round, Series C, of $1.8M.
- Exit Acquired by Biocartis.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pronota
Complete news archive for Pronota
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pronota
Pronota was founded in 2004 and raised its 1st funding round 2 years after it was founded.
Pronota is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.
Pronota is a funded company, having raised a total of $34.75M across 10 funding rounds to date. The company's 1st funding round was a Series A of $7.8M, raised on Apr 2006.
Pronota has 2 employees.
Pronota NV was founded in 2004 in Ghent, Belgium, within the medical diagnostics sector. Early detection of conditions including heart failure, pre-eclampsia, and sepsis is facilitated through proprietary, non-invasive tests. Biological samples proteomes are analyzed to develop a range of diagnostic products. Operations emphasize diagnosis and personalized healthcare, with services targeted at patient validation and portfolio expansion in Europe.
Pronota has 10 investors. Key investors include Biocartis, Gimv, VIB, Life Sciences Partners, and KBC Private Equity.
Pronota operates through Mycartis Nv.
Yes. Pronota was acquired by Biocartis in September 2014.

